Introduction
============

Acute myeloid leukemia (AML) is composed of a group of diseases with marked morphological and cytogenetic heterogeneity that account for \~20% of childhood and adolescent acute leukemias ([@b1-ol-0-0-5162],[@b2-ol-0-0-5162]). Acute promyelocytic leukemia (APL) is considered a distinct subtype of AML, with a particular cytological morphology (M and M3 variant in the French-American-British classification) ([@b3-ol-0-0-5162]). APL is characterized by a specific chromosome translocation, t(15;17), which results in the rearrangement of the promyelocytic leukemia (PML) gene and the retinoic acid receptor α (RARα) gene, followed by the expression of the PML-RARα chimeric protein ([@b4-ol-0-0-5162]). Despite the fact that majority of APL cases can achieve complete remission when treated with conventional chemotherapy by all-trans retinoic acid (ATRA) and/or arsenic trioxide (As~2~O~3~) ([@b5-ol-0-0-5162]--[@b8-ol-0-0-5162]), certain clinical cases exhibit acquired resistance and APL relapse ([@b5-ol-0-0-5162],[@b6-ol-0-0-5162],[@b8-ol-0-0-5162]), and the detailed molecular mechanisms have not been completely elucidated.

The small ubiquitin-like modifier (SUMO)/sentrin-specific protease (SENP) family includes six SENPs named SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7, which have different substrate specificities and subcellular localizations in mammalian cells ([@b9-ol-0-0-5162]). It has been reported that SENP1 is important in placental development and erythropoiesis ([@b10-ol-0-0-5162],[@b11-ol-0-0-5162]). In addition, SENP1 could control adipocyte differentiation via de-SUMOylation modification ([@b12-ol-0-0-5162]), and is important in protecting against myocardial ischemia/reperfusion injury via a hypoxia-inducible factor 1α-dependent pathway ([@b13-ol-0-0-5162]). Numerous studies have demonstrated that SENP1 is overexpressed and contributes significantly to the development and progression of tumors, including prostatic intraepithelial neoplasia, colon cancer and pancreatic cancer ([@b14-ol-0-0-5162]--[@b16-ol-0-0-5162]). Previous studies have revealed that deficiency or downregulation of SENP1 could induce radiosensitization in lung cancer cells ([@b17-ol-0-0-5162]), promote endoplasmic reticulum (ER) stress-induced apoptosis in MEF and HEK 293T cells ([@b18-ol-0-0-5162]), and increase apoptosis in Burkitt lymphoma cells ([@b19-ol-0-0-5162]). Furthermore, SENP1 is also involved in the formation of PML protein nuclear bodies ([@b20-ol-0-0-5162],[@b21-ol-0-0-5162]), which were originally characterized as part of a fusion protein with PML-RARα in patients with APL ([@b22-ol-0-0-5162]). However, whether SENP1 is a potential drug target for APL treatment still remains unclear.

ER stress has been implicated in diverse diseases, including cancer, diabetes, cerebral ischemia, and neurodegenerative and cardiovascular diseases ([@b23-ol-0-0-5162],[@b24-ol-0-0-5162]). In addition to the intrinsic and extrinsic apoptosis pathways, ER stress-induced apoptosis has recently been reported as another major pathway mediating cell apoptosis ([@b25-ol-0-0-5162]), and is involved in arsenic-induced apoptosis of osteoblasts, myoblasts, pancreatic cells, myeloma cells, and drug-sensitive and drug-resistant leukemia cells ([@b26-ol-0-0-5162]--[@b30-ol-0-0-5162]). It has been suggested that As~2~O~3~ can induce human lens cell apoptosis by the ER stress-initiated process ([@b31-ol-0-0-5162]).

In the present study, the NB4 cell line (an APL cell line from a relapsed APL patient) was utilized as an *in vitro* model ([@b32-ol-0-0-5162]). It was demonstrated that As~2~O~3~ could induce ER stress-initiated apoptosis in NB4 cells, which was significantly upregulated by SENP1 knockdown. In addition, it was observed that SENP1 specifically de-SUMOylated X-box binding protein 1 (XBP1) and played a critical role during As~2~O~3~-induced ER stress. Taken together, our results revealed the roles of SENP1 in APL and the potential effects of clinical APL treatment by targeting SENP1.

Materials and methods
=====================

### Antibodies and reagents

RPMI-1640 medium, Dulbecco\'s modified Eagle medium, trypsin and TRIzol were obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Puromycin and fetal bovine serum (FBS) were purchased from Gibco (Thermo Fisher Scientific, Inc.). As~2~O~3~ was provided by Beijing Shuanglu Pharmaceutical Co., Ltd. (Beijing, China). Radioimmunoprecipitation assay lysates were purchased from Beyotime Institute of Biotechnology (Haimen, China). ATRA, phenylmethylsulfonyl fluoride, aprotinin, leupeptin and pepstatin were acquired from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). Protein A/G PLUS-Agarose was obtained from Roche Diagnostics (Indianapolis, IN, USA). Anti-XBP1 antibody (cat. no. H00007494-D01) and anti-SUMO-1 antibody (cat. no. AJ1746a) were purchased from Abnova (Taipei City, Taiwan) and Abgent Biotech Co., Ltd. (Suzhou, China), respectively. The FITC Annexin V Apoptosis Detection kit and the anti-cluster of differentiation (CD) 11b antibody (cat. no. C09-550019) were commercially available from BD Pharmingen (San Diego, CA, USA). The PrimeScript RT reagent kit and SYBR Green PCR Master Mix were commercially available from Takara Bio, Inc. (Otsu, Japan).

### Cell culture

Human APL NB4 cells (American Type Culture Collection, Manassas, VA, USA) were suspended at 5×10^5^ cells/ml in RPMI-1640 medium supplemented with 10% FBS. Retrovirus containing SENP1 small interfering RNA (siRNA) or nonspecific control (NC) siRNA, as described previously ([@b10-ol-0-0-5162]), was transfected into NB4 cells to generate si-SENP1-transfected NB4 cells (si-SENP1) or NC siRNA-transfected cells (si-NC) upon puromycin (0.75 µg/ml) selection. All cells were cultured in RPMI-1640 medium with 10% FBS at 37°C in 5% CO~2~.

### As~2~O~3~ and ATRA treatment

NB4 cells were seeded into a 6-well plate and then incubated with As~2~O~3~ (1 µM) or ATRA (1 µM) for different time periods, as indicated. A total of 10^6^ cells were harvested at different time points subsequent to As~2~O~3~ or ATRA treatment.

### Flow cytometry

For apoptosis assay, cells treated with As~2~O~3~ at each indicated time point were washed twice with ice-cold phosphate-buffered saline, and the apoptotic cells were detected with a flow cytometer (Merck Millipore) using the FITC Annexin V Apoptosis Detection kit according to the manufacturer\'s protocol. For CD11b assay, cells were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-CD11b antibody (1:100) after treatment with ATRA for 24 h. Appropriate isotype control IgG2b antibodies (cat. no. NB810-82278; Novus Biologicals LLC, Littleton, CO, USA) were used. The percentage of apoptotic cells and the differentiation marker of cell surface expression were analyzed using Guava 1.0 software (Guava Technologies, Inc., Hayward, CA, USA).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated with TRIzol, and complementary DNA was synthesized using TaKaRa RNA PCR kit (Takara Bio, Inc.) according to the manufacturer\'s protocol. The sequences of the PCR primers used in the amplification of the target genes are shown in [Table I](#tI-ol-0-0-5162){ref-type="table"}. RT-qPCR was performed with the double-stranded DNA dye SYBR Green PCR core reagents using the ABI ViiA 7 system (PerkinElmer, Inc., Waltham, MA, USA). Thermal cycler conditions were 95°C for 30 sec, and 40 cycles of 95°C for 5 sec and 60°C for 30 sec. Relative gene expression was determined by the delta delta Cq method (Applied Biosystems; Thermo Fisher Scientific, Inc.), with β-actin as the endogenous control using the Applied Biosystems ViiA™ 7 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) ([@b16-ol-0-0-5162]). Three independent experiments were performed, and the standard deviations (SDs) representing experimental errors were calculated. All data were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

### Immunoprecipitation

Treated cells were lysed with lysis buffer, and immunoprecipitation using anti-XBP1 and anti-SUMO-1 antibodies was performed as previously reported ([@b33-ol-0-0-5162],[@b34-ol-0-0-5162]). Briefly, cell lysates were centrifuged at 10,800 × *g* for 15 min at 4^º^C, and the supernatant was collected. Protein concentrations were determined by means of Lowry protein assay. Equal amounts of protein samples (1 mg) were incubated with 2 µg antibody for 3 h at 4^º^C, followed by addition of pre-equilibrated Protein A/G PLUS-Agarose beads (20 µl) and incubation overnight. The immunoprecipitates were washed four times with lysis buffer, and the bound proteins were boiled in 15 µl 2X sodium dodecyl sulfate (SDS) sample buffer, eluted and resolved on 10% SDS-polyacrylamide gel electrophoresis. The proteins were transferred onto a polyvinylidene fluoride membrane and probed with horseradish peroxidase (HRP)-phytohemagglutinin-L (Thermo Fisher Scientific, Inc.) and HRP-concanavalin A lectin (Abnova), and then detected using an enhanced chemiluminescence kit (Pierce Biotechnology, Inc., Rockford, IL, USA).

### Statistical analyses

The data were presented as the mean ± SD. Statistical analysis was performed using GraphPad Prism 5 software. The paired *t*-test was used to compare the difference between two different groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### SENP1 deficiency has no effect on the spontaneous apoptosis or differentiation of NB4 cells

The fact that SENP1 was overexpressed in several neoplastic tissues ([@b14-ol-0-0-5162]--[@b16-ol-0-0-5162]) raised the question whether SENP1 plays any role in the pathogenesis of APL. Thus, a SENP1-knockdown NB4 cell line (si-SENP1) was generated by stably transfecting SENP1 siRNA into NB4 cells. Compared with the NB4 cells transfected with NC scrambled siRNA (si-NC), the messenger RNA (mRNA) expression of SENP1 was significantly downregulated to \~45% in si-SENP1 NB4 cells ([Fig. 1A](#f1-ol-0-0-5162){ref-type="fig"}). A series of flow cytometry assays were performed to explore whether SENP1 deficiency would promote spontaneous apoptosis and differentiation in NB4 cells. Firstly, the percentage of apoptotic si-NC and si-SENP1 NB4 cells was examined by flow cytometry following annexin V-FITC and propidium iodide (PI) staining. As shown in [Fig. 1B](#f1-ol-0-0-5162){ref-type="fig"}, knockdown of SENP1 had no effect on the spontaneous apoptosis of NB4 cells compared with si-NC cells. Next, the effects of SENP1 deficiency on NB4 cell differentiation were examined by detecting the expression levels of a differentiation marker, CD11b. The results from cytometry revealed no difference in the expression of CD11b between si-NC and si-SENP1 NB4 cells, even after treatment with 1 µΜ ATRA (a differentiation inducing agent) for 24 h ([Fig. 1C](#f1-ol-0-0-5162){ref-type="fig"}). These results suggested that the downregulation of SENP1 has no effect on the spontaneous apoptosis or differentiation of NB4 cells.

### SENP1 deficiency promotes As~2~O~3~-induced NB4 cell apoptosis

As~2~O~3~ has been successfully used in the treatment of APL ([@b7-ol-0-0-5162],[@b35-ol-0-0-5162],[@b36-ol-0-0-5162]), and therapeutic doses of As~2~O~3~ could effectively induce complete molecular remission *in vivo* and trigger the apoptotic death of APL cells ([@b37-ol-0-0-5162]). Thus, we sought to investigate if the knockdown of SENP1 affects As~2~O~3~-induced apoptosis in NB4 cells. Therefore, normal and SENP1 knocked down NB4 cells treated with As~2~O~3~ were collected and subjected to flow cytometry assay upon annexin V-FITC and PI staining. As shown in [Fig. 2A](#f2-ol-0-0-5162){ref-type="fig"}, after treatment with As~2~O~3~ for 3 days, the apoptotic cells in the si-NC NB4 group only increased by 2.90-fold (from 12.92±1.00 to 37.00±2.00%), while in the si-SENP1 NB4 group, the apoptotic cells increased by ≤4.00-fold (from 16.62±1.00 to 66.00±3.00%). The total number of apoptotic cells was \~30% in si-SENP1 cells compared with that in si-NC cells ([Fig. 2B](#f2-ol-0-0-5162){ref-type="fig"}), suggesting that SENP1 is essential for NB4 cell survival during treatment with As~2~O~3~.

### SENP1 regulates the expression of XBP1 target genes in the ER stress-mediated apoptotic pathway

Numerous studies have revealed that As~2~O~3~ induces cell apoptosis through the ER stress pathway ([@b28-ol-0-0-5162],[@b29-ol-0-0-5162],[@b31-ol-0-0-5162]). Thus, we assumed that As~2~O~3~-induced apoptosis may also accompany ER stress. Several key players, including CCAAT-enhancer-binding protein homologous protein \[also known as growth arrest and DNA damage inducible protein 153 (GADD153)\], activating transcription factor 6 (ATF6) and 78 kDa glucose-regulated protein (GRP78), as well as XBP1 target genes, including ER-localized DnaJ 4 (Erdj4), Sec61a and ER degradation enhancer, mannosidase (Edem), are common markers that reflect the unfolded protein response during ER stress ([@b38-ol-0-0-5162],[@b39-ol-0-0-5162]). Therefore, to investigate the effects of SENP1 on the ER stress-mediated apoptotic pathway, the mRNA expression levels of the above proteins were detected by RT-qPCR in si-NC and si-SENP1 NB4 cells subsequent to treatment with As~2~O~3~ for different time periods. As shown in [Fig. 3](#f3-ol-0-0-5162){ref-type="fig"}, the mRNA expression levels of these markers were highly increased by \~4.00-fold (GRP78), 1.77-fold (GADD153), 1.80-fold (Erdj4) and 1.80-fold (Sec61a) in si-NC cells after As~2~O~3~ treatment for 1 day, but no effect on ATF6 or Edem ([Fig. 3C and F](#f3-ol-0-0-5162){ref-type="fig"}) were observed, and upregulation was also observed in si-SENP1 NB4 cells, which revealed that As~2~O~3~ induced NB4 cell apoptosis through the ER stress-mediated apoptotic pathway. Additionally, among the XBP1 target genes, the mRNA expression levels of Erdj4 and Sec61a were significantly reduced by knockdown of SENP1 following As~2~O~3~ treatment in si-SENP1 NB4 cells ([Fig. 3B and D](#f3-ol-0-0-5162){ref-type="fig"}).

### SENP1 deficiency upregulates XBP1 SUMOylation in si-SENP1 NB4 cells

Since the mRNA expression levels of XBP1 target genes, including Erdj4 and Sec61a, were significantly reduced in si-SENP1 NB4 cells upon As~2~O~3~ treatment, the present study next sought to explore whether XBP1 could be SUMOylated in si-SENP1 NB4 cells. As shown in [Fig. 4](#f4-ol-0-0-5162){ref-type="fig"}, in contrast to si-NC cells ([Fig. 4](#f4-ol-0-0-5162){ref-type="fig"}, lanes 2 and 3), XBP1 was partly SUMOylated following immunoprecipitation with an anti-SUMO-1 antibody in si-SENP1 NB4 cells ([Fig. 4](#f4-ol-0-0-5162){ref-type="fig"}, lanes 4 and 5). The input sample for immunoprecipitation was directly loaded to reveal the appropriate location of the protein bands of interest ([Fig. 4](#f4-ol-0-0-5162){ref-type="fig"}, lane 1). These findings suggested that SENP1 deficiency may downregulate XBP1 transactivation by increasing XBP1 SUMOylation.

Discussion
==========

APL is characterized by a specific t(15;17) chromosomal translocation that yields the PML/RARA fusion gene ([@b3-ol-0-0-5162]). It has been reported that \>97% of APL patients have the t(15;17) translocation, and several rare variant translocations observed in the remaining APL patients always involve RARα ([@b3-ol-0-0-5162],[@b40-ol-0-0-5162]). As~2~O~3~ is an effective treatment for this disease, since it could induce SUMO-dependent ubiquitin-mediated proteasomal degradation of PML-RARα ([@b41-ol-0-0-5162]). However, knockdown of SENP1 had no effect on the SUMOylation of PML-RARα in NB4 cells, even after NB4 cells were treated with 1 µΜ As~2~O~3~ (data not shown), suggesting the possibility that other members of the SENP family may be involved in regulating the level of SUMOylated PML-RARα, which remains to be further investigated. It has been reported that knockdown of SENP1 could promote drug-induced cell apoptosis in MEF and HEK 293T cells, as well as lung cancer and Burkitt lymphoma cells ([@b17-ol-0-0-5162]--[@b19-ol-0-0-5162]). However, our results revealed that downregulation of SENP1 had no effect on the spontaneous apoptosis or differentiation of NB4 cells ([Fig. 1](#f1-ol-0-0-5162){ref-type="fig"}). Furthermore, it was observed that downregulation of SENP1 had no impact on drug-induced apoptosis or differentiation in NB4 cells ([Fig. 1](#f1-ol-0-0-5162){ref-type="fig"}).

The metabolism of As~2~O~3~ in APL cells is complex ([@b42-ol-0-0-5162]). Production of intracellular methylated metabolites and epigenetic changes of DNA methylation during As~2~O~3~ metabolism may contribute to the therapeutic efficacy of As~2~O~3~ in APL ([@b43-ol-0-0-5162]). The signaling cascades and transcription factors related to As~2~O~3~-induced apoptosis were caused by reactive oxygen species formation ([@b44-ol-0-0-5162],[@b45-ol-0-0-5162]), resulting in the stimulation of apoptosis in leukemia cells. In contrast to the observation that inhibition of phosphoinositide 3-kinase (PI3K)/Akt could increase As~2~O~3~-induced apoptosis of APL cells ([@b46-ol-0-0-5162],[@b47-ol-0-0-5162]), in the present study, it was observed that downregulation of SENP1 could promote As~2~O~3~-induced NB4 cell apoptosis, suggesting that there may be pathways other than PI3K/Akt contributing to the effect of SENP1 on As~2~O~3~-treated APL cells. Numerous studies have demonstrated that As~2~O~3~ could induce cell apoptosis through the ER stress pathway ([@b28-ol-0-0-5162],[@b29-ol-0-0-5162],[@b31-ol-0-0-5162],[@b48-ol-0-0-5162]). Consistently, in our study, the upregulation of key markers of the ER stress-mediated apoptotic pathway in si-SENP1 NB4 cells indicated that As~2~O~3~ could induce NB4 cell apoptosis through the ER stress-mediated apoptotic pathway. Notably, the high ER stress induced by As~2~O~3~ treatment at day 1 in the present study led to significant cell apoptosis at day 3, which may be explained by the sustained effect of As~2~O~3~-induced apoptosis. SUMOylation is a dynamic process that is reversed by proteins of the SENP family, which can be catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes ([@b49-ol-0-0-5162]). The modification of proteins with SUMO plays pivotal roles in modulating the activation, function and subcellular localization of these proteins ([@b50-ol-0-0-5162]). The transcription factor XBP1 is a key component of the ER stress response and a critical transcription factor that drives the transcription of various genes ([@b51-ol-0-0-5162],[@b52-ol-0-0-5162]). Additionally, XBP1 can be activated in MEF and HEK 293T cells via the de-SUMOylation function of SENP1 ([@b18-ol-0-0-5162]). Therefore, it would be reasonable to assume the existence of an intrinsic mechanism by which the downregulation of SENP1 affects cell apoptosis in the treatment of APL with As~2~O~3~. Our data suggested that SENP1 regulated XBP1 transactivation by regulating the expression of XBP1 target genes, and that SENP1 may play a specific role in regulating XBP1 activity during As~2~O~3~-induced apoptosis. Of note, SENP1 downregulation also reduced the expression of the transcription factor GRP78, which was involved in the ER stress response after As~2~O~3~ treatment for 1 day ([Fig. 3C](#f3-ol-0-0-5162){ref-type="fig"}), suggesting that SENP1 and its downstream signaling pathway may affect other transcription factors involved in ER stress.

Taken together, our study provided the first evidence for As~2~O~3~-induced NB4 cell apoptosis through the ER stress-mediated apoptotic pathway, and demonstrated that SENP1 downregulation promoted As~2~O~3~-induced NB4 cell apoptosis. The knockdown of SENP1 also increased the levels of accumulated SUMOylated XBP1, which was accompanied by downregulation of the mRNA expression and transcriptional activity of XBP1 target genes, which were involved in ER stress response and closely linked to the apoptosis of NB4 cells. Our data also provided insight into potential therapeutic targets for APL treatment via manipulating XBP1 signaling during ER stress by targeting SENP1.
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![SENP1 deficiency has no effect on the spontaneous apoptosis or differentiation of NB4 cells. (A) mRNA expression level of SENP1 in cells transfected with si-SENP1 and cells transfected with si-NC. (B) Spontaneous apoptosis of NB4 cells transfected with si-SENP1 and si-NC. (C) Positive expression rate of CD11b in NB4 cells induced by ATRA for 72 h. \*\*P\<0.01, *t*-test. SENP1, small ubiquitin-like modifier/sentrin-specific protease 1; mRNA, messenger RNA; NC, nonspecific control; si, small interfering; PI, propidium iodide; FITC, fluorescein isothiocyanate; CD, cluster of differentiation; ATRA, all-trans retinoic acid; CON, control; iso, isotype; NS, not significant.](ol-12-05-3755-g00){#f1-ol-0-0-5162}

![SENP1 deficiency promotes As~2~O~3~-induced NB4 cell apoptosis. (A) Apoptosis of the si-NC and si-SENP1 NB4 cells was analyzed by flow cytometry. (B) The number of apoptotic si-SENP1 cells was significantly higher than that of the si-NC cells, following treatment with As~2~O~3~ for 3 d.\*\*P\<0.01, *t*-test. SENP1, small ubiquitin-like modifier/sentrin-specific protease 1; NC, nonspecific control; si, small interfering; PI, propidium iodide; FITC, fluorescein isothiocyanate; NS, not significant; As~2~O~3~, arsenic trioxide; d, day.](ol-12-05-3755-g01){#f2-ol-0-0-5162}

![Expression levels of ER stress-related key markers (A) GRP78, (B) Erdj4, (C) ATF6, (D) Sec61a, (E) GADD153 and (F) Edem in SENP1-deficient cells treated with As~2~O~3~. \*\*P\<0.01; \*P\<0.05, *t*-test. SENP1, small ubiquitin-like modifier/sentrin-specific protease 1; GADD153, growth arrest and DNA damage inducible protein 153; ATF6, activating transcription factor 6; GRP78, 78 kDa glucose-regulated protein; ErdJ4, ER-localized DnaJ 4; Edem, ER degradation enhancer, mannosidase; NC, nonspecific control; si, small interfering; NS, not significant; As~2~O~3~, arsenic trioxide; mRNA, messenger RNA; ER, endoplasmic reticulum.](ol-12-05-3755-g02){#f3-ol-0-0-5162}

![SENP1 deficiency upregulates XBP1 SUMOylation in NB4 si-NC (lanes 2 and 3) and si-SENP1 (lanse 4 and 5) cells treated with (lanes 3 and 5) or without (lanes 2 and 4) As~2~O~3~. SENP1, SUMO/sentrin-specific protease 1; SUMO, small ubiquitin-like modifier; XBP1, X-box binding protein 1; Con, control; IgG, immunoglobulin; IP, immunoprecipitation; IB, immunoblotting; As~2~O~3~, arsenic trioxide; si, small interfering.](ol-12-05-3755-g03){#f4-ol-0-0-5162}

###### 

Sequences of the primers used in the amplification of the target genes.

  Locus     Primers (5′-3′)
  --------- -----------------------------------
  β-actin   \(F\) CTTTTCCAGCCTTCCTTCTTGG
            \(R\) CAGCACTGTGTTGGCATAGAGG
  SENP1     \(F\) ATCAGGCAGTGAAACGTTGGAC
            \(R\) ATCAGGCAGTGAAACGTTGGAC
  GADD153   \(F\) GAAACGGAAACAGAGTGGTCATTCCCC
            \(R\) GTGGGATTGAGGGTCACATCATTGGCA
  ATF6      \(F\) ATGAAGTTGTGTCAGAGAAC
            \(R\) GGGTGCTATTGTAATGACTCA
  GRP78     \(F\) AGTTGATATTGGAGGTGGGC
            \(R\) CATTGAAGTAAGCTGGTACAGTAAC
  Erdj4     \(F\) CCCCAGTGTCAAACTGTACCAG
            \(R\) AGCGTTTCCAATTTTCCATAAATT
  Sec61a    \(F\) CTATTTCCAGGGCTTCCGAGT
            \(R\) AGGTGTTGTACTGGCCTCGGT
  Edem      \(F\) AAGCCCTCTGGAACTTGCG
            \(R\) AACCCAATGGCCTGTCTGG

F, forward; R, reverse; SENP1, Small ubiquitin-like modifier/sentrin-specific protease 1; GADD153, growth arrest and DNA damage inducible protein 153; ATF6, activating transcription factor 6; GRP78, 78 kDa glucose-regulated protein; ErdJ4, ER-localized DnaJ 4; Edem, ER degradation enhancer, mannosidase; ER, endoplasmic reticulum.
